KalVista appoints Bilal Arif as COO and Linea Aspesi as Chief People Officer

KalVista Pharmaceuticals, Inc.

Bilal Arif appointed COO effective Oct 6, 2025; base salary $520k, annual bonus target 40%, option grant of 100,000 shares.
Linea Aspesi appointed Chief People Officer; also receives inducement option grant of 100,000 shares.
Both options vest over 4 years: 1/4th on 1-year anniversary, then monthly vesting.
Appointments support global launch of EKTERLY for hereditary angioedema.
Arif was EVP at Sarepta Therapeutics; Aspesi was Chief Admin Officer at Editas Medicine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.